Analyses of larger patient cohorts are required to validate the use of ZEB1 as a predictive marker in order to stratify BRAF‐mutated melanoma into MAPKi‐sensitive and MAPKi‐resistant subgroups. This evidence concerns the gene BRAF and melanoma.